Ono Pharmaceutical Co. Ltd.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagen...
Latest News
8 days ago · businesswire.com
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid ModulatorOSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that ONO-1110, an endocannabinoid modulator, demonstrated efficacy signals in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), and Hunner-type interstitial cystitis (HIC). Additional Phase 2 clinical studies of ONO-1110 were conducted in major depressive disorder (MDD) and social anxiety disorder (SAD). Although the ONO-111.
2 months ago · businesswire.com
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”). Under the terms of the agreement, Aitia will utilize its REFS™ technology to build Gemini Digital Twins (GDTs) of neurological diseases and identify new therapeutic targets and bio.
Earnings
Add to Watchlist
Select watchlists to add or remove OPHLY